Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

NCT06114329 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: AL01211

Sponsor

AceLink Therapeutics, Inc.